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Tools which estimate the risk of stroke in patients with atrial fibrillation are widely used in clinical practice to 
help in the choice of antithrombotic strategy.1–3 One of the 
most commonly used is the cardiac failure, hypertension, 
age, diabetes mellitus, stroke (doubled) [CHADS2] score.2 
Although CHADS2 and other scores include cardiac failure 
or congestive heart failure (HF), it is unclear how HF should 
be defined and whether it is an independent risk factor for 
thromboembolism.4–9
Clinical Perspective on p 460
In a pooled analysis of 3 trials, moderate to severe 
echocardiographic left ventricular systolic dysfunction 
(LVSD) was an independent risk factor for stroke in patients 
with atrial fibrillation, although this was not confirmed in all 
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Background—We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left 
ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin.
Methods and Results—The risk of a number of outcomes, including the composite of SSE or death (to take account of 
competing risks) and composite of SSE, major bleeding, or death (net clinical benefit) were calculated in 3 patient groups: 
(1) no HF/no LVSD (n=8728), (2) HF/no LVSD (n=3207), and (3) LVSD with/without symptomatic HF (n=2736). The 
rate of both outcomes was highest in patients with LVSD (SSE or death 8.06; SSE, major bleeding, or death 10.46 per 100 
patient-years), intermediate for HF but preserved LV systolic function (5.32; 7.24), and lowest in patients without HF or 
LVSD (1.54; 5.27); each comparison P<0.0001. Each outcome was less frequent in patients treated with apixaban: in all 
ARISTOTLE patients, the apixaban/warfarin hazard ratio for SSE or death was 0.89 (95% confidence interval, 0.81–0.98; 
P=0.02); for SSE, major bleed, or death it was 0.85 (0.78–0.92; P<0.001). There was no heterogeneity of treatment effect 
across the 3 groups.
Conclusions—Patients with LVSD (with/without HF) had a higher risk of SSE or death (but similar rate of SSE) compared 
with patients with HF but preserved LV systolic function; both had a greater risk than patients without either HF or 
LVSD. Apixaban reduced the risk of both outcomes more than warfarin in all 3 patient groups.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984. (Circ Heart Fail. 
2013;6:451-460.)
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subsequent studies.10–14 Moreover, several analyses have shown 
that clinical HF is not an independent risk factor for stroke in 
patients with atrial fibrillation although left ventricular (LV) 
function was not documented in most of these studies and it is 
likely that patients with preserved, as well as reduced ejection 
fraction (EF) were included among those with HF.4–14
To further examine the relationship among ventricular func-
tion, clinical HF, and the risk of stroke or systemic embolism 
(SSE) in patients with atrial fibrillation, we undertook a ret-
rospective analysis of the Apixaban for Reduction in Stroke 
and Other Thromboembolic Events in Atrial Fibrillation trial 
(ARISTOTLE).15,16 We also examined the effect of apixaban, 
compared with warfarin, according to LV function and HF status.
Methods
Patients
The design and results of ARISTOTLE have been reported in de-
tail.15,16 In brief, ARISTOTLE was a double-blind, double-dummy, 
randomized trial comparing apixaban 5 mg twice daily (or 2.5 mg 
twice daily for patients with ≤2 of the following 3 criteria: age, ≥80 
years; body weight, ≤60 kg; or serum creatinine level, ≥1.5 mg/dL) 
with warfarin (dosed by the investigator to achieve a target interna-
tional normalized ratio, 2.0–3.0) in patients with atrial fibrillation 
at risk of stroke. The inclusion criteria were persistent or paroxys-
mal atrial fibrillation and 1 or more of the following risk factors for 
stroke: age, ≥75 years; prior stroke, transient ischemic attack (TIA), 
or systemic embolism; symptomatic HF within 3 months; LVSD that 
is, EF ≤40%; diabetes mellitus; or hypertension requiring pharmaco-
logical treatment. Reasons for exclusion included atrial fibrillation 
because of a reversible cause; mitral stenosis, a prosthetic heart valve 
or other indication for oral anticoagulation; need for aspirin in a dose 
>165 mg/d or combined with clopidogrel; recent stroke (<7 days); 
increased risk of hemorrhage; anemia with hemoglobin <9 g/dL; cre-
atinine clearance <25 mL/min; active liver disease; other comorbid 
condition with reduced life expectancy and inability to comply with 
international normalized ratio monitoring or other study procedures. 
Institutional review board approval and patient written informed con-
sent were obtained before enrolment.
Trial Outcomes
The primary efficacy outcome was stroke (ischemic or hemor-
rhagic) or systemic embolism. The key secondary efficacy outcome 
was death from any cause. The primary safety outcome was major 
bleeding, defined using the International Society on Thrombosis 
and Hemostasis criteria. Another predefined efficacy outcome was 
the composite of stroke, systemic embolism, or death. The follow-
ing net clinical benefit composite outcomes were also prespecified: 
stroke, systemic embolism, or major bleeding and stroke, systemic 
embolism, major bleeding or death from any cause. All primary and 
secondary efficacy and safety outcome events were adjudicated by a 
blinded clinical events committee using prespecified criteria.
For this analysis, we also report HF hospitalizations. These were 
not adjudicated events and but were designated the primary reason for 
admission by the trial investigators.
Definition of LVSD and HF
Information on investigator reported HF and ventricular function was 
obtained from the trial case report forms. Information on HF was avail-
able from the Inclusion Criteria page (symptomatic congestive HF 
within 3 months) and the Cardiovascular Disease History page (Does 
the subject have symptomatic congestive HF?). Similarly, information 
on LV function was obtained from the Inclusion Criteria page (LV dys-
function with an EF ≤40% by echocardiography, radionuclide study, or 
contrast angiography) and the Assessment of Left Ventricular Function 
page which recorded EF or LV dysfunction category (normal, mild, 
moderate, or severe), whether an evaluation of LV function had been 
made. Only patients with a report of both HF status and LV function 
were included in this analysis. These patients were divided into 3 cate-
gories: (1) patients with LVSD, with or without symptomatic HF. LVSD 
was defined as an EF ≤40% or a report of moderate or severe LVSD; 
(2) patients with HF and preserved EF (>40%), normal LV function, or 
mild LVSD, collectively referred to as HF with preserved EF (HF-PEF); 
and (3) patients with no HF and an EF >40% or normal LV function 
(ie, with neither LVSD nor HF-PEF). The ARISTOTLE prespecified 
efficacy and safety outcomes were analyzed post hoc in each of these 
patient groups, as was the effect of apixaban compared with warfarin.
Statistical Analysis
Baseline characteristics were summarized using medians and quar-
tiles for continuous variables and frequencies and percentages for 
categorical variables. These characteristics were compared across 
patient groups using Kruskal–Wallis and ANOVA tests. Efficacy 
and safety end points are presented as rates per 100 patient-years of 
follow-up. Hazard ratios (HRs) comparing the LVSD and HF-PEF 
groups with the reference group (no LVSD/no HF) were derived from 
a Cox proportional hazards model. Withal models were unadjusted 
except SSE where the following variables were used to derive ad-
justed HRs for the SSE end point: age, sex, hypertension, diabetes 
mellitus, coronary artery disease (any of prior myocardial infarc-
tion, percutaneous coronary intervention, or coronary artery bypass 
grafting), history of stroke/TIA, body mass index, and renal func-
tion (eGFR [estimated glomerular filtration rate]). The interactions 
between the randomized treatment and patient group were computed 
using a Cox proportional hazards model, which included the random-
ized treatment, the patient group, and the interaction between the 2 as 
covariates. Statistical analyses were performed at the Duke Clinical 
Research Institute using SAS software version 9.22 (SAS Institute, 
Inc, Cary, NC). All tests were 2-sided and a P value of <0.05 was 
considered statistically significant.
Results
A total of 18 201 patients were randomized, of which 14 671 
(81%) had information on both HF status and LV systolic 
function. Of these 14 671 patients, 8728 (59%) had no report 
of symptomatic HF and an EF >40% (n=7473) or normal 
LV systolic function (n=1101) or mild dysfunction (n=154). 
A further 3207 patients (22%) had a report of symptomatic 
HF and an EF >40% (n=2971) or normal LV systolic func-
tion (n=181) or mild dysfunction (n=55; ie, the study defini-
tion of HF-PEF. Finally, 2736 patients (19%) had an EF ≤40% 
(n=2623) or moderate or severe dysfunction (n=113). Of these 
2736 patients, 1865 (13%) had a report of symptomatic HF 
and 871 (5.9%) had asymptomatic LVSD.
The median overall follow-up in ARISTOTLE was 18 
months.
Baseline Characteristics
Patients With LVSD and HF-PEF
The baseline characteristics of patients with LVSD (with or 
without symptomatic HF), patients with HF and HF-PEF and 
those with neither LVSD nor HF (no LVSD/no HF) are shown 
in Table 1.
Compared with patients with LVSD, patients with HF-PEF 
were twice as likely to be women, were more likely to have 
a history of hypertension (although had a similar baseline 
blood pressure) and more often treated with a calcium 
channel blocker. Conversely, patients with LVSD were more 
likely than those with HF-PEF to have a history of myocardial 
infarction or revascularization procedure, have anemia and 
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Table 1. Baseline Characteristics
LVSD (n=2736) HF-PEF (n=3207) No LVSD/No HF (n=8728) P Value*
Age (median, 25th–75th) 68 (60–74) 69 (61–75) 71 (64–76) <0.0001
Age ≥75 y, n (%) 641 (23) 811 (25) 2944 (34) <0.0001
Female, n (%) 583 (21) 1354 (42) 3068 (35) <0.0001
Systolic blood pressure (median, 25th–75th), 
mm Hg
126 (114–138) 130 (120–140) 130 (120–140) <0.0001
Diastolic blood pressure (median, 25th–75th), 
mm Hg
80 (70–85) 80 (71–88) 80 (70–86) <0.0001
Body mass index (median, 25th–75th), kg/m2 28.1 (24.7–32.0) 29.3 (25.8–33.5) 28.5 (25.3–32.5) <0.0001
Diabetes mellitus, n (%) 736 (27) 808 (25) 2182 (25) 0.13
Hypertension, n (%) 2059 (75) 2851 (89) 7845 (90) <0.0001
Documented coronary artery disease, n (%) 1172 (43) 1537 (48) 2538 (29) <0.0001
History of at least moderate valvular  
disease, n (%)
817 (30) 800 (25) 1504 (17) <0.0001
 Mitral regurgitation 754 (28) 690 (22) 1255 (14) <0.0001
 Mitral stenosis 17 (<1) 34 (1) 75 (1) 0.19
 Aortic regurgitation 171 (6) 210 (7) 361 (4) <0.0001
 Aortic stenosis 57 (2) 95 (3) 170 (2) 0.0033
Left BBB, n (%) 307 (11) 156 (5) 254 (3) <0.0001
Prior myocardial Infarction, n (%) 763 (28) 572 (18) 934 (11) <0.0001
Prior percutaneous coronary  
intervention, n (%)
380 (14) 249 (8) 890 (10) <0.0001
Prior coronary artery bypass graft, n (%) 339 (12) 182 (6) 576 (7) <0.0001
Implantable cardioverter defibrillator, n (%) 223 (8) 27 (1) 47 (<1) <0.0001
Resynchronization device, n (%) 81 (3) 11 (<1) 11 (<1) <0.0001
Prior stroke or TIA, n (%) 432 (16) 560 (17) 1710 (20) <0.0001
Anemia, n (%) 216 (8) 267 (8) 637 (7) 0.15
Current smoker, n (%) 302 (11) 265 (8) 653 (7) <0.0001
Type of atrial fibrillation, n (%)
 Paroxysmal 295 (11) 473 (15) 1642 (19) <0.0001
 Persistent or permanent 2441 (89) 2732 (85) 7085 (81)
Prior use of vitamin K antagonists, n (%) 1656 (61) 1627 (51) 5459 (63) <0.0001
Current NYHA Class, n (%)
 I 731 (27) 529 (16) 6374 (73) <0.0001
 II 1373 (50) 1974 (62) 2127 (24)
 III 598 (22) 681 (21) 205 (2)
 IV 33 (1) 23 (<1) 4 (<1)
LV ejection fraction (median, 25th–75th; 
n=12 900), n (%)
35 (30–39) 56 (50–62) 60 (55–65) <0.0001
LV dysfunction classification [n=1714], n (%)
 Normal 16 (7) 181 (77) 1101 (88)
 Mild 14 (6) 55 (23) 154 (12)
 Moderate 123 (55) 0 (0) 0 (0)
 Severe 70 (31) 0 (0) 0 (0)
CHADS (mean, SD) 2.22 (1.20) 2.67 (1.08) 1.88 (0.99) <0.001
 1 803 (29) 284 (9) 3880 (45) <0.0001
 2 986 (36) 1404 (44) 2911 (33)
 ≥3 947 (35) 1519 (47) 1937 (22)
(Continued)
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to be treated with a β-blocker and digoxin (although these 
differences were small). Patients with LVSD were also more 
likely than those with HF-PEF to have left bundle-branch 
block on their ECG and to have an implanted cardioverter 
defibrillator.
By definition, more patients with HF-PEF were in New 
York Heart Association functional class II–IV and had a 
higher median EF (56%) than those with LVSD (35%).
Patients with LVSD were more likely to have persistent (as 
opposed to paroxysmal AF) than patients with HF-PEF and 
more likely to have received a vitamin K antagonist before 
randomization.
There was a substantial difference in the distribution of 
CHADS2 score between patients with LVSD and those with 
HF-PEF. The proportion of patients with a score of 1 was 
29.4% among those with LVSD compared with 8.9% among 
those with HF-PEF.
Patients With Neither LVSD Nor HF-PEF
Patients without either LVSD or HF-PEF were older than 
those in the other 2 groups, less likely to have coronary heart 
or valvular disease and more likely to have a history of prior 
stroke or TIA. These patients were also less likely to be 
treated with an ACE (angiotensin-converting enzyme) inhibi-
tor/ARB (angiotensin receptor blocker), β-blocker, diuretic, 
amiodarone, or aspirin (but more likely than any other group 
to be treated with a calcium channel blocker). By definition, 
more patients in this group than in any other were in New 
York Heart Association functional class I and had the highest 
median EF (60%). This group also had the greatest proportion 
Table 1. (Continued)
LVSD (n=2736) HF-PEF (n=3207) No LVSD/No HF (n=8728) P Value*
Creatinine clearance, n (%)
 Normal (80 mL/min) 1127 (41) 1390 (43) 3670 (42) <0.0001
 Mild impairment (>50–80 mL/min) 1103 (41) 1259 (39) 3698 (43)
 Moderate impairment (>30–50 mL/min) 442 (16) 478 (15) 1239 (14)
 Severe impairment (≤30 mL/min) 52 (2) 72 (2) 86 (1)
Medications at time of randomization, n (%)
 ACE inhibitor or ARB 2205 (81)  2473 (77) 5802 (66) <0.0001
 Amiodarone 417 (15) 418 (13) 812 (9) <0.0001
 β-Blocker 2043 (75) 2199 (69) 5381 (62) <0.0001
 Aspirin 938 (34) 1026 (32) 2618 (30) <0.0001
 Clopidogrel 66 (2) 59 (2) 168 (2) 0.22
 Digoxin 1299 (47) 1258 (39) 2102 (24) <0.0001
 Calcium blocker 430 (16) 846 (26) 3245 (37) <0.0001
 Statin 1184 (43) 1203 (38) 4032 (46) <0.0001
 Diuretic 1992 (73) 2235 (70) 4000 (46) <0.0001
 Aldosterone antagonist 62 (2) 46 (1) 42 (<1) <0.0001
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BBB, bundle branch block; CHADS, cardiac failure, hypertension, age, diabetes 
mellitus, stroke; HF-PEF, heart failure with preserved ejection fraction; LVSD, left ventricular systolic dysfunction; NYHA, New York Heart Association; and TIA, transient 
ischemic attack.
*For continuous variables derived from the Kruskal–Wallis test except for CHADS scores (ANOVA).
Figure. Cumulative incidence of the pri-
mary composite outcome of stroke or sys-
temic embolism in the 3 patient groups: (1) 
no heart failure (HF)/no left ventricular sys-
tolic dysfunction (LVSD), (2) HF/no LVSD, 
and (3) LVSD with/without symptomatic HF.
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of patients with paroxysmal atrial fibrillation and by far the 
largest proportion (44.5%) with a CHADS2 score of 1.
Unadjusted Clinical Outcomes
Unadjusted rates of SSE did not differ significantly across the 
3 patient groups (Table 2; Figure). The rate of death was high-
est in those with LVSD, intermediate in patients with HF-PEF, 
and lowest in subjects with neither LVSD nor HF-PEF. The 
rate of death was also substantially higher than the rate of SSE 
in all groups. The relative difference was greatest in patients 
with LVSD. The rate of the composite outcomes, including 
death, showed the same pattern across patient groups as death.
Of the 1865 subjects with LVSD and symptomatic HF, 44 
experienced SSE (rate 1.35 per 100 patient-years) compared 
Table 2. Association Between HF/LSVD Status and Efficacy, Safety, and Net Benefit Outcomes
LVSD HF-PEF No LVSD/No HF
P ValueRate* (n) HR† (95% CI) Rate* (n) HR† (95% CI) Rate* (n)
Efficacy end points
  Stroke or systemic 
embolism‡
1.39 (67) 1.01 (0.77–1.33) 1.52 (89) 1.11 (0.87–1.42) 1.37 (224) 0.71
 Stroke 1.29 (62) 0.98 (0.74–1.30) 1.39 (81) 1.06 (0.82–1.36) 1.31 (214) 0.89
  Ischemic/uncertain 
type stroke
1.00 (48) 1.02 (0.74–1.41) 1.11 (65) 1.14 (0.86–1.52) 0.97 (159) 0.67
 Hemorrhagic stroke 0.29 (14) 0.81 (0.45–1.46) 0.31 (18) 0.86 (0.51–1.46) 0.35 (58) 0.72
 Systemic embolism 0.10 (5) 1.21 (0.44–3.37) 0.14 (8) 1.61 (0.67–3.84) 0.08 (14) 0.71
  Death from any 
cause
7.07 (348) 2.96 (2.57–3.42) 4.32 (258) 1.81 (1.55–2.11) 2.40 (400) <0.0001
  Stroke, systemic 
embolism or death 
from any cause
8.06 (389) 2.33 (2.05–2.65) 5.32 (311) 1.54 (1.34–1.77) 3.46 (565) <0.0001
Safety end points
 ISTH major bleeding 3.09 (135) 1.23 (1.01–1.50) 2.55 (134) 1.02 (0.84–1.24) 2.50 (372) 0.11
  Intracranial 0.45 (20) 0.75 (0.46–1.22) 0.45 (24) 0.75 (0.48–1.18) 0.60 (90) 0.30
  Other location 2.63 (115) 1.38 (1.11–1.72) 2.09 (110) 1.10 (0.88–1.37) 1.89 (282) 0.01
  Gastrointestinal 0.95 (42) 1.46 (1.02–2.10) 0.81 (43) 1.26 (0.88–1.80) 0.64 (97) 0.10
  Major or clinically 
relevant nonmajor 
bleeding
5.53 (237) 1.12 (0.97–1.30) 5.27 (271) 1.07 (0.93–1.23) 4.88 (712) 0.26
  GUSTO severe 
bleeding
0.81 (36) 0.99 (0.68–1.44) 0.75 (40) 0.92 (0.65–1.32) 0.81 (122) 0.91
  GUSTO moderate/
severe bleeding
2.04 (90) 1.18 (0.93–1.50) 1.61 (85) 0.93 (0.73–1.19) 1.72 (258) 0.26
 TIMI major bleeding 1.36 (60) 1.03 (0.77–1.37) 1.26 (67) 0.96 (0.73–1.27) 1.31 (197) 0.92
  TIMI major or minor 
bleeding
2.25 (99) 1.15 (0.91–1.44) 1.91 (101) 0.98 (0.78–1.23) 1.95 (292) 0.45
 Any bleeding 21.27 (777) 0.95 (0.88–1.03) 20.70 (907) 0.93 (0.86–1.00) 22.15 (2691) 0.11
Net benefit end points
  Stroke, systemic 
embolism, or major 
bleeding
4.15 (195) 1.20 (1.02–1.41) 3.85 (220) 1.12 (0.96–1.31) 3.44 (550) 0.07
  Stroke, systemic 
embolism, major 
bleeding or death 
from any cause
10.46 (492) 1.98 (1.77–2.22) 7.24 (414) 1.37 (1.22–1.54) 5.27 (843) <0.0001
Other end points
 HF hospitalization 5.99 (274) 5.07 (4.21–6.11) 3.24 (185) 2.77 (2.26–3.40) 1.12 (189) <0.0001
CI indicates confidence interval; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; ISTH, International 
Society on Thrombosis and Hemostasis; HF-PEF, heart failure with preserved ejection fraction; HR, hazard ratio; LVSD, left ventricular systolic dysfunction; TIA, transient 
ischemic attack; and TIMI, Thrombolysis In Myocardial Infarction.
*Rate per 100 patient-years of follow-up.
†Hazard ratio vs no LVSD/no HF group.
‡Adjusted for age, sex, hypertension, diabetes mellitus, coronary artery disease (any of prior myocardial infarction, percutaneous coronary intervention, or coronary 
artery bypass grafting), history of stroke/TIA, body mass index and renal function (eGFR [estimated glomerular filtration rate]).
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with 23 among the 871 individuals with asymptomatic LVSD 
(rate 1.49 per 100 patient-years). For the composite of death 
or SSE, these figures were 295 (9.02 per 100 patient-years) 
and 94 (6.05 per 100 patient-years), respectively.
The rate of hospitalization for HF was 2- to 4-fold higher than 
the rate of SSE in patients with LVSD and HF-PEF, but was 
lower than the rate of SSE in patients with neither LVSD nor HF.
The rate of bleeding did not differ significantly between 
patient groups and although the net clinical benefit outcome 
did, the difference was mainly driven by death.
Adjusted Clinical Outcomes
For the SSE end point, the adjusted rates (per 100/person-
years of follow-up) were 1.53, 1.58, and 1.38 for the LVSD, 
HF-PEF, and no LVSD/no HF groups, respectively. Although 
the difference among the 3 groups was not statistically signifi-
cant (P=0.52), regardless of treatment, patients in the LVSD 
and HF-PEF groups had a slightly higher rate of SSE during 
follow-up—HR (95% confidence interval), 1.10 (0.83–1.46) 
for LVSD and 1.15 (0.89–1.48) for HF-PEF.
The relationship between EF, examined as a continuous vari-
able, and risk of SSE was not statistically significant—the HR 
for each 10% decrease in LVEF was 1.02 (0.94–1.11); P=0.65.
Comparison of Apixaban With Warfarin
The effect of apixaban, compared with warfarin, on the effi-
cacy and safety outcomes is shown in Tables 3 through 5. 
For all the prespecified efficacy composite outcomes, the HR 
favored apixaban in each patient group, with no evidence of 
heterogeneity of treatment effect. This was also the case for 
all-cause mortality alone. In the whole ARISTOTLE popu-
lation, the apixaban/warfarin HR for SSE or death was 0.89 
(95% confidence interval, 0.81–0.98); P=0.02. The HR also 
favored apixaban for all definitions of bleeding (except gas-
trointestinal bleeding in patients with HF-PEF) and all net 
clinical benefit outcomes in each patient group. In the whole 
ARISTOTLE population, the apixaban/warfarin HR for SSE, 
major bleed, or death was 0.85 (0.78–0.92); P<0.001.
Compared with warfarin, apixaban had no effect on HF 
hospitalization.
Table 3. Treatment Effect by HF/LSVD Status—Efficacy End Points
Rate (n)
HR (95% CI) Interaction P ValueApixaban Warfarin
Stroke or systemic embolism*
 LVSD 0.99 (24) 1.80 (43) 0.55 (0.34–0.91) 0.21
 HF-PEF 1.51 (44) 1.54 (45) 0.98 (0.65–1.49)
 No LVSD/no HF 1.16 (95) 1.58 (129) 0.74 (0.57–0.96)
Stroke
 LVSD 0.91 (22) 1.67 (40) 0.54 (0.32–0.91) 0.22
 HF-PEF 1.37 (40) 1.40 (41) 0.98 (0.63–1.51)
 No LVSD/no HF 1.09 (89) 1.54 (125) 0.71 (0.54–0.93)
Ischemic or uncertain type stroke
 LVSD 0.79 (19) 1.21 (29) 0.65 (0.36–1.15) 0.27
 HF-PEF 1.20 (35) 1.03 (30) 1.17 (0.72–1.91)
 No LVSD/no HF 0.87 (71) 1.08 (88) 0.81 (0.59–1.10)
Hemorrhagic stroke
 LVSD 0.12 (3) 0.45 (11) 0.27 (0.08–0.97) 0.64
 HF-PEF 0.20 (6) 0.41 (12) 0.50 (0.19–1.34)
 No LVSD/no HF 0.24 (20) 0.46 (38) 0.53 (0.31–0.91)
Systemic embolism
 LVSD 0.08 (2) 0.12 (3) 0.67 (0.11–3.99) 0.80
 HF-PEF 0.14 (4) 0.14 (4) 1.01 (0.25–4.02)
 No LVSD/no HF 0.10 (8) 0.07 (6) 1.34 (0.47–3.86)
Death from any cause
 LVSD 6.99 (172) 7.15 (176) 0.98 (0.79–1.21) 0.52
 HF-PEF 4.05 (121) 4.58 (137) 0.89 (0.69–1.13)
 No LVSD/no HF 2.17 (181) 2.62 (219) 0.83 (0.68–1.01)
Stroke, systemic embolism or death from any cause
 LVSD 7.76 (188) 8.37 (201) 0.93 (0.76–1.13) 0.63
 HF-PEF 5.07 (148) 5.57 (163) 0.91 (0.73–1.14)
 No LVSD/no HF 3.14 (256) 3.79 (309) 0.83 (0.70–0.98)  
CI indicates confidence interval; HF-PEF, heart failure with preserved ejection fraction; HR, hazard ratio; and LVSD, left ventricular systolic dysfunction.
*Adjusted for age, sex, hypertension, diabetes mellitus, coronary artery disease (any of prior myocardial infarction, percutaneous coronary intervention or coronary 
artery bypass grafting), history of stroke/TIA, body mass index and renal function (eGFR [estimated glomerular filtration rate]).
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Discussion
We found that among a large cohort of patients with atrial 
fibrillation receiving an oral anticoagulant, unadjusted rates of 
SSE in those with LVSD or HF-PEF were not higher than in 
those without LVSD or HF. However, the stroke risk-factor 
profile differed considerably among these 3 patient groups.
As anticipated, patients with HF-PEF differed from those 
with LVSD, particularly with respect to the proportion of 
women and those with a history of hypertension, both of 
which were greater in subjects with HF-PEF.17 These 2 fac-
tors, plus a higher proportion of patients with symptomatic HF 
and slightly more elderly individuals, resulted in the HF-PEF 
Table 4. Treatment Effect by HF/LSVD Status—Safety End Points
Rate (n)
HR (95% CI) Interaction P ValueApixaban Warfarin
ISTH major bleeding
 LVSD 2.77 (61) 3.41 (74) 0.81 (0.58–1.14) 0.50
 HF-PEF 1.95 (52) 3.17 (82) 0.62 (0.44–0.88)
 No LVSD/no HF 2.17 (162) 2.83 (210) 0.77 (0.62–0.94)
ISTH major bleeding: intracranial
 LVSD 0.18 (4) 0.73 (16) 0.25 (0.08–0.73) 0.23
 HF-PEF 0.15 (4) 0.76 (20) 0.20 (0.07–0.58)
 No LVSD/no HF 0.38 (29) 0.81 (61) 0.47 (0.30–0.73)
ISTH major bleeding: other location
 LVSD 2.59 (57) 2.67 (58) 0.97 (0.67–1.40) 0.64
 HF-PEF 1.80 (48) 2.39 (62) 0.76 (0.52–1.10)
 No LVSD/no HF 1.78 (133) 2.01 (149) 0.89 (0.70–1.12)
ISTH major bleeding: gastrointestinal
 LVSD 0.81 (18) 1.09 (24) 0.74 (0.40–1.36) 0.043
 HF-PEF 1.08 (29) 0.53 (14) 2.03 (1.07–3.84)
 No LVSD/no HF 0.59 (45) 0.70 (52) 0.86 (0.57–1.27)
Major or clinically relevant nonmajor bleeding
 LVSD 5.05 (109) 6.01 (128) 0.84 (0.65–1.08) 0.23
 HF-PEF 4.09 (107) 6.50 (164) 0.63 (0.50–0.81)
 No LVSD/no HF 3.90 (287) 5.89 (425) 0.66 (0.57–0.77)
GUSTO severe bleeding
 LVSD 0.49 (11) 1.14 (25) 0.43 (0.21–0.88) 0.88
 HF-PEF 0.45 (12) 1.07 (28) 0.42 90.21–0.83)
 No LVSD/no HF 0.54 (41) 1.08 (81) 0.50 (0.34–0.73)
GUSTO moderate/severe bleeding
 LVSD 1.71 (38) 2.38 (52) 0.72 (0.47–1.09) 0.74
 HF-PEF 1.20 (32) 2.03 (53) 0.59 (0.38–0.92)
 No LVSD/no HF 1.29 (97) 2.16 (161) 0.60 (0.46–0.77)
TIMI major bleeding
 LVSD 1.07 (24) 1.64 (36) 0.65 (0.39–1.10) 0.92
 HF-PEF 0.93 (25) 1.60 (42) 0.59 (0.36–0.96)
 No LVSD/no HF 0.97 (73) 1.66 (124) 0.58 (0.44–0.78)
TIMI major or minor bleeding
 LVSD 1.85 (41) 2.66 (58) 0.69 (0.46–1.03) 0.83
 HF-PEF 1.42 (38) 2.42 (63) 0.59 (0.40–0.88)
 No LVSD/no HF 1.57 (118) 2.34 (174) 0.67 (0.53–0.85)
Any bleeding
 LVSD 18.72 (356) 24.03 (421) 0.79 (0.68–0.91) 0.48
 HF-PEF 17.03 (391) 24.75 (516) 0.70 (0.61–0.80)
 No LVSD/no HF 18.55 (1171) 26.04 (1520) 0.73 (0.67–0.78)  
CI indicates confidence interval; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; HF-PEF, heart 
failure-preserved ejection fraction; HR, hazard ratio; ISTH, International Society on Thrombosis and Hemostasis; LVSD, left ventricular systolic dysfunction; and TIMI, 
Thrombolysis In Myocardial Infarction.
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group having higher overall CHADS2 scores. Conversely, 
patients with LVSD had a considerably higher mortality 
rate. Consequently, direct comparison of outcomes in these 
2 groups is difficult because of their quite different and com-
peting risks, on the one hand of SSE (in those with HF-PEF) 
and on the other of death (in those with LVSD). Comparison 
with these 2 groups is further confounded by the fact that to 
be enrolled in ARISTOTLE, individuals with neither HF nor 
LVSD had to have other risk factors for SSE. As a result, the 
no LVSD/no HF group were older and had higher frequen-
cies of hypertension and diabetes mellitus than might have 
been expected (compared with patients in the HF-PEF and 
LVSD groups). For the same reason, subjects without LVSD 
or HF-PEF had the highest frequency of prior stroke or TIA.
Consequently, evaluation of the independent influence of 
symptomatic HF and LVSD on the risk of SSE required multi-
variable adjustment. After adjustment, we found that patients 
with LVSD and those with HF-PEF had a numerically higher 
risk of SSE than patients with neither LVSD nor HF. Of inter-
est, the adjusted stroke rate was similar in patients with LVSD 
and HF-PEF, although the difference between these 2 patient 
groups and those without either LVSD or HF-PEF was not 
significant. When EF was examined as a continuous variable, 
there was no apparent relationship with SSE, a finding consis-
tent with a recent large study from France.18 Indeed, it is uncer-
tain that any transthoracic echocardiographic measure is an 
independent predictor of stroke.11–13,19,20 However, N-terminal 
pro B-type natriuretic peptide was shown to be an indepen-
dent predictor of stroke risk in the Randomized Evaluation 
of Long-Term Anticoagulation Therapy trial, although in that 
analysis only HF was adjusted for and ventricular function 
was not taken into account.21
Despite our findings, we cannot definitively conclude that 
the clinical syndrome of HF or reduced systolic function do 
not increase the risk of SSE. All patients in ARISTOTLE 
received an oral anticoagulant, so it is possible that this treat-
ment largely abrogated the risk of SSE related to LVSD or HF, 
and LVSD and HF could be risk factors for SSE in patients not 
receiving an anticoagulant.
One other notable observation in this analysis was that the 
rate of hospitalization for HF was 2- to 4-fold higher than 
the rate of SSE in patients with LVSD and HF-PEF, but in 
patients with neither LVSD nor HF, the rate of SSE was 
higher than the rate of HF hospitalization. It is also of inter-
est to compare the rates of death and stroke in ARISTOTLE 
with those in the recently reported warfarin versus aspirin 
in patients with Reduced Cardiac Ejection Fraction trial 
(WARCEF) in patients with systolic HF but in sinus rhythm. 
The rate of death in warfarin-treated patients in WARCEF was 
6.63% per year compared with 7.15 in patients with LVSD in 
ARISTOTLE. The rate of ischemic stroke in WARCEF was 
0.72% per year compared with 1.21 (ischemic or unknown 
cause of stroke) in ARISTOTLE. The higher rates of both 
events in ARISTOTLE might reflect the older average age, 
presence of clinically evident atrial fibrillation, and a greater 
proportion of patients with prior stroke or TIA compared with 
WARCEF.
The second objective of our analyses was to compare the 
effects of apixaban with those of warfarin on the prespeci-
fied ARISTOTLE efficacy and safety outcomes across the 
patient groups of interest. In keeping with the overall results 
of ARISTOTLE, we found that apixaban was superior to war-
farin with respect to both types of outcome and there was no 
evidence of treatment heterogeneity according to LV function 
or HF status. The figures illustrating composite outcomes, 
including death (which take account of competing risks), 
demonstrate that patients treated with apixaban fare better 
than those receiving warfarin and that patients with HF-PEF 
and particularly those with LVSD have the greatest absolute 
benefit (because they are at higher absolute risk).
Our study had a number of limitations. First, it was a retro-
spective analysis. Second, 19% of patients did not have base-
line information on both LV systolic function and HF status. 
Third, our definition of HF relied on an investigator diagnosis 
indicated by a check-box and did not fulfil all the criteria rec-
ommended in guidelines. Fourth, because of relatively small 
numbers, we had to combine patients with both symptomatic 
and asymptomatic LVSD.
Table 5. Treatment Effect by HF/LSVD Status—Net Benefit and Other End points
Rate (n)
HR (95% CI) Interaction P ValueApixaban Warfarin
Stroke, systemic embolism, or major bleeding
 LVSD 3.69 (87) 4.62 (108) 0.80 (0.60–1.05) 0.98
 HF-PEF 3.46 (99) 4.24 (121) 0.82 (0.63–1.06)
 No LVSD/no HF 3.04 (243) 3.85 (307) 0.79 (0.67–0.94)
Stroke, systemic embolism, major bleeding, or death from any cause
 LVSD 10.11 (239) 10.81 (253) 0.93 (0.78–1.12) 0.59
 HF-PEF 6.71 (192) 7.76 (222) 0.86 (0.71–1.05)
 No LVSD/no HF 4.78 (383) 5.76 (460) 0.83 (0.73–0.95)
HF hospitalization
 LVSD 5.89 (135) 6.10 (139) 0.96 (0.76–1.21) 0.62
 HF-PEF 3.29 (94) 3.19 (91) 1.03 (0.78–1.38)
 No LVSD/no HF 1.24 (101) 1.08 (88) 1.15 (0.87–1.54)  
CI indicates confidence interval; HF-PEF, heart failure-preserved ejection fraction; HR, hazard ratio; and LVSD, left ventricular systolic dysfunction.
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In summary, anticoagulated patients with atrial fibrilla-
tion and LVSD and those with atrial fibrillation and HF-PEF 
had a numerically higher adjusted risk of SSE than patients 
with neither LVSD nor HF, although the difference between 
the patient groups was not significant. Similarly, there was 
no relationship between risk of SSE and EF considered as a 
continuous measure. Apixaban was superior to warfarin with 
respect to both efficacy and safety outcomes in all patient 
groups, with the greatest absolute benefit in the highest risk 
patients with LVSD.
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CLINICAL PERSPECTIVE
We investigated the risk of stroke or systemic embolism in patients with atrial fibrillation and heart failure treated with either 
warfarin or the direct factor Xa inhibitor apixaban in the Apixaban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation Trial (ARISTOTLE). Patients with heart failure had a numerically (but not statistically signifi-
cant) higher risk of stroke or systemic embolism than those without heart failure. The risk of stroke or systemic embolism in 
heart failure was similar in patients with preserved and reduced ejection fraction. The superiority of apixaban over warfarin 
with respect to both efficacy and safety (bleeding) was consistent in patients with and without heart failure. Apixaban is 
an alternative to warfarin for prevention of stroke or systemic embolism in patients with atrial fibrillation and heart failure.
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